246 related articles for article (PubMed ID: 38324115)
1. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment.
Rajaeinejad M; Parhizkar-Roudsari P; Khoshfetrat M; Kazemi-Galougahi MH; Mosaed R; Arjmand R; Mohsenizadeh SA; Arjmand B
Cardiovasc Toxicol; 2024 Feb; 24(2):184-198. PubMed ID: 38324115
[TBL] [Abstract][Full Text] [Related]
2. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
3. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
4. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine-Associated Cardiotoxicity.
Kanduri J; More LA; Godishala A; Asnani A
Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
[TBL] [Abstract][Full Text] [Related]
7. [Cardiotoxicity of 5-fluorouracil: report of 6 cases].
Timour Q; Lombard-Bohas C; Slim R; Barel C; Bui-Xuan B; Tabib A; Bricca G; Malonne H; Vial T; Iordescu D; Descotes J
Therapie; 2002; 57(3):302-6. PubMed ID: 12422546
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
10. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
More LA; Lane S; Asnani A
Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861
[TBL] [Abstract][Full Text] [Related]
11. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
Saif MW
Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601
[TBL] [Abstract][Full Text] [Related]
12. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease.
Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of the antiproliferative compound fluorouracil.
Becker K; Erckenbrecht JF; Häussinger D; Frieling T
Drugs; 1999 Apr; 57(4):475-84. PubMed ID: 10235688
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of 5-fluorouracil].
Pan L; Yang X; Song H
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
Khan MA; Masood N; Husain N; Ahmad B; Aziz T; Naeem A
J Pak Med Assoc; 2012 May; 62(5):430-4. PubMed ID: 22755303
[TBL] [Abstract][Full Text] [Related]
18. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.
Dyhl-Polk A; Schou M; Vistisen KK; Sillesen AS; Serup-Hansen E; Faber J; Klausen TW; Bojesen SE; Vaage-Nilsen M; Nielsen DL
Oncologist; 2021 Mar; 26(3):e403-e413. PubMed ID: 32959474
[TBL] [Abstract][Full Text] [Related]
19. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
